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Ronald Frank2, Florenz Sasse2 and Andreas Meyerhans1,5*Abstract
Background: The nuclear export of unspliced and partially spliced HIV-1 mRNA is mediated by the recognition of a
leucine-rich nuclear export signal (NES) in the HIV Rev protein by the host protein CRM1/Exportin1. This makes the
CRM1-Rev complex an attractive target for the development of new antiviral drugs. Here we tested the anti-HIV
efficacy of ratjadone A, a CRM1 inhibitor derived from myxobacteria.
Results: Ratjadone A inhibits HIV infection in vitro in a dose-dependent manner with EC50 values at the nanomolar
range. The inhibitory effect of ratjadone A occurs around 12 hours post-infection and is specific for the
Rev/CRM1-mediated nuclear export pathway. By using a drug affinity responsive target stability (DARTS) assay we
could demonstrate that ratjadone A interferes with the formation of the CRM1-Rev-NES complex by binding to
CRM1 but not to Rev.
Conclusion: Ratjadone A exhibits strong anti-HIV activity but low selectivity due to toxic effects. Although this limits
its potential use as a therapeutic drug, further studies with derivatives of ratjadones might help to overcome these
difficulties in the future.
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The HIV-encoded Rev protein is a trans-acting nuclear fac-
tor that plays a pivotal role in the virus post-transcriptional
regulation [1]. Through specific interactions with RanGT-
Pase-dependent cellular mediators, Rev mediates the trans-
port of unspliced and partially spliced viral mRNAs to the
host-cell cytoplasm (Figure 1A). Rev shuttles in and out of
the nucleus via two distinct signals: an arginine-rich nuclear
localization signal (NLS) in the Rev RNA-binding domain,
and a leucine-rich nuclear export signal (NES) found in
the Rev-activation domain [2]. Rev enters the nucleus by
direct binding of its NLS to the human nuclear import
receptor, importin-β [3]. Inside the nucleus, Rev binds to
the Rev-responsive element (RRE)-containing HIV mRNAs* Correspondence: andreas.meyerhans@upf.edu
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article, unless otherwise stated.forming a complex that hides the Rev NLS signal and ex-
poses its NES for recognition by the nuclear export medi-
ator Exportin1/CRM1 [4]. This interaction triggers the
transfer of unspliced and partially spliced viral mRNAs to
the cytoplasm [5,6] for the subsequent translation of HIV
structural proteins and encapsidation.
A functional Rev-CRM1 cooperation is critical for HIV
replication [3,7-12]. Although several nuclear export
mediators have been described [4], the CRM1 pathway
is selectively used for the Rev-dependent nuclear export
of HIV-1 mRNAs [2]. Deletions in both the N- and C-
terminal domains of Rev impair virus replication [13]
and Rev mutants that are unable to multimerize do not
localize to the nucleus [14,15]. Similarly, both importin-β
and CRM1 mutants have been shown to block nuclear
import and export pathways despite a functional NES-
carrying partner [16-19]. Treatment with CRM1 inhibi-
tors, such as leptomycin B (LMB) [19,20], has shown to
block HIV replication in vitro [7,8], although toxicity-entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Schematic representation of Rev-mediated nuclear export of HIV mRNAs and chemical structures of RaTA and LMB. (A)
Binding of the Nuclear Localization Signal (NLS) in Rev to importin-β (Imp-β) triggers the nuclear internalization of Rev through the Nuclear Pore
Complex (NPC). Once in the nucleus, Rev binds to the Rev-responsive element (RRE) of the HIV mRNA. This interaction exposes the Nuclear Export
Signal (NES) of Rev for recognition by CRM1. The CRM1-Rev-mRNA complex is stabilized by the phosphorylated form of Ran (RanGTP) and crosses
the nuclear pore into the cytoplasm where Ran is dephosphorylated (RanGDP) and the complex is disassembled making HIV mRNAs available for
translation. (B) The specific groups within the chemical structures of RaTA and LMB that are involved in the interaction with CRM1 are circled. A
complete description of these interactions can be found in (55). Structures are freely available from: http://www.chemspider.com. Chemspider IDs:
5293127 and 4948244.
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these compounds as antiviral drugs.
In this work we report the anti-HIV efficacy of ratja-
done A (denoted here as RaTA), a CRM1 inhibitor pro-
duced by the myxobacterium Sorangium cellulosum [21]
that shares structural similarities with LMB (Figure 1B).
Myxobacteria are a group of bacteria from soil that can
be considered as microbial cell factories. Their fermenta-
tion has been optimized to improve the yield and diversity
of large amounts of secondary metabolites with interesting
biological functions [22-24]. The anti-HIV activity of
these metabolites has recently been evaluated by a high-
throughput two-step infectivity assay [25]. Amongst the
hits were ratjadones A, B, C and D that previously have
been shown to exhibit antibiotic effects against fungi and
growth inhibition of mammalian cancer cells with the
same mode of action as LMB [26]. However, RaTA has
been suggested to be more potent and less toxic than
LMB [27]. These differences in activities between RaTA
and LMB could be due to structural changes at carbon C8
and a tale of different size and polarity (Figure 1B) [27].
Thus, putative anti-HIV effects of RaTA may differ from
LMB. We show here that RaTA inhibits HIV replicationin vitro in a dose-dependent manner with higher potency
than LMB. RaTA interferes with the HIV mRNA nuclear
export step by binding to CRM1 but not to Rev.
Results
Ratjadone A (RaTA) inhibits HIV infection in vitro
To analyse the antiviral potency of RaTA, a TZM-bl in-
fectivity test was performed as previously described
[25]. The TZM-bl cell-based assay measures the anti-
viral activity of small molecules as a function of reduc-
tions in the HIV Tat-regulated luciferase reporter gene
expression [28]. Cells were pre-treated with 10-fold ser-
ial dilutions of RaTA or LMB as control and infected
with HIVLAI at a MOI of 0.5. HIV-dependent luciferase
activity was measured 48 h after the infection. Similar
to the effect of leptomycin B (LMB), the inhibition of
HIV-infection by RaTA was dose-dependent from con-
centrations of 0.1 nM up to 10 to 100 nM above which
no luciferase signal could be detected (Figure 2A and 2B).
Cell toxicity appeared at concentrations above 1 nM.
Normalized mean luciferase values (% of DMSO control)
from two independent experiments were used to evaluate
relative drug potency. The calculated EC50 and CC50 for
Figure 2 Potency of ratjadone A against HIV infection of TZM-bl cells. Cells were seeded in 96-well plates in triplicate and treated with
increasing concentrations of RaTA (A) or LMB (B) and infected with HIVLAI at a multiplicity of infection (MOI) of 0.5. 48 h after infection cells were
assayed for luciferase activity and the mean relative light units (RLU) were plotted as % relative to DMSO (vehicle) for both infectivity and cell
viability. Effective Concentration 50 (EC50) and Cytotoxic Concentration 50 (CC50) were estimated by non-linear regression of log inhibitor vs.
normalized response and used to calculate the Selectivity Index (SI) value (see Materials and methods). Bars: standard error of the mean (SEM).
For panels (C) and (D), cells were HIV infected by spinoculation, seeded in 6-well plates and treated with increasing concentrations of RaTA. 48 h
after infection, cells were lysed and analysed by Western Blotting (C). HIV p24 bands are shown in the upper row. Lanes 1 to 3: cells incubated
with RaTA at different concentrations; Lane 4: DMSO control; Lane 5: uninfected DMSO control. Tubulin was used as a loading control (lower
row). Every band in panel C was normalized respect to the loading control and quantified. The relative p24 production was plotted as % relative
to DMSO control (D). The drug solvent concentration (0.1% DMSO) in every sample was constant.
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6.8 nM and 16 nM for LMB. Although the calculated SI
value was similar for both drugs (2.7 for RaTA and 2.3 for
LMB), RaTA exhibited an overall 4-fold higher potency
than LMB in the TZM-bl cells assay (Figure 2A and 2B).
It is known that luciferase-mRNA requires the CRM1-
nuclear export pathway to be expressed [29]. Since the
TZM-bl infection-assay is based on the luciferase ex-
pression induced upon HIV infection [28], the calculated
inhibitory values for the test compounds could be biased.
To confirm that the observed antiviral activity of RaTA
was not due to an unspecific luciferase inhibition, we
tested the effect of RaTA on the production of the HIV
capsid protein p24 in a Western Blot (Figure 2C and 2D).
At 10 nM RaTA, the HIV p24 production was reduced
to about 10% relative to the solvent control. This inhib-
ition is identical to that measured in the TZM-bl assay
(Figure 2A), thus excluding an unspecific artefact from
the assay system used.
Ratjadone A decreases HIV p24 production in MT-2 cells
To further confirm the antiviral activity of RaTA in a
T-cell line, MT-2 cells were pre-treated with RaTA or
LMB at concentrations of 2 nM and 4 nM respectively
or left untreated (MOCK control), and infected withHIV. After 48 h, HIV p24 production was analysed by
immunofluorescence. Un-infected control cells showed
very low background signals (Figure 3A), compared to
the intense p24 signals of the infected control cells
(Figure 3B). In contrast, treatment with RaTA or LMB
significantly inhibited HIV p24 production (Figure 3C-D).
Although it has been described that drug EC50 estimations
vary among different cell types, these results are consistent
with the HIV inhibition observed in the TZM-bl cell assay
and further ruled out the possibility of unspecific effects
on luciferase expression and activity.
Ratjadone A inhibits HIV at the mRNA nuclear export step
To corroborate that the step of the replication cycle
targeted by RaTA is the nuclear export of HIV mRNAs,
we performed a time-of-drug-addition experiment (TOA)
in TZM-bl cells. TOA is a critical assay that helps identify
the mode of action and putative secondary targets of new
antiviral drugs [30]. In this assay, drugs are added at differ-
ent time points after synchronized infections and the
drug’s inhibitory effect on viral replication is measured
72 h later. A drug-mediated viral inhibition is visible up to
a time point corresponding to the replication step targeted
by the drug. If the drug is added after it’s targeted replica-
tion step, viral replication will not be inhibited and a
Figure 3 Ratjadone A inhibits HIV p24 expression in
MT-2-infected cells. MT-2 cells were infected with HIVLAI and
treated with ratjadone A or leptomycin B. 48 h after infection cells
were fixed and stained for HIV-p24 protein (green signals) and with
DAPI (blue signals). Not infected and infected but untreated cells were
used as negative and positive controls respectively. (A) non-infected
cells. (B) p24 distribution in infected cells without drugs. (C) p24
distribution in infected cells treated with ratjadone A, and (D) p24
distribution in infected cells treated with leptomycin B.
Figure 4 Ratjadone A blocks HIV infection at a time point
corresponding to viral mRNA nuclear export. TZM-bl cells were
synchronously infected with HIVLAI and plated in 96-wells plates in
duplicate. Then 10 nM ratjadone A or 1 μM T20 were added at the
indicated time points. The drug solvent (0.1% DMSO) was used as
control. 72 h after infection luciferase activity was measured for every
time point. Values are plotted as relative light units per seconds of
exposure and are the mean of the duplicates. Error bars are standard
error of the mean (SEM).
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[30,31]. Briefly, cells were spinoculated with HIV at 4°C,
washed and dispensed into 96-well plates. Infection was
synchronized by addition of culture medium at 37°C and
drugs were added at the indicated time points. The infect-
ivity curves are shown in Figure 4. The anti-HIV action of
RaTA occurs around 12 h after synchronized infection, a
time-point coinciding with the HIV-RNA nuclear export
step [31]. The HIV-entry inhibitor Enfuvirtide T20 was
used as a positive control for the TOA assay. T20 has a
well-defined mechanism of action that results in a charac-
teristic TOA infectivity curve [31]. Our results werecomparable (Figure 4) demonstrating the accuracy of our
experimental conditions and assay outputs. Variations
seen in the infection recovery after the time of drug action
are commonly observed in TOA experiments and can be
due to residual effects of the drugs when targeting a re-
petitive process that takes place for hours [31]. Depending
on factors such as affinity and concentration, individual
drugs can have more than one effective target, thus affect-
ing additional steps in the virus replication cycle. It has
been described that increasing concentrations of an anti-
viral drug might saturate its primary target and that re-
sidual unbound drug can then be available for blocking
additional viral processes [31]. This effect will be evident
in TOA by a change in the shape of the time-response
curve. At the concentration tested here, RaTA does not
seem to target additional steps of the HIV replication
cycle.
Ratjadone A inhibits the Rev-dependent HIV mRNA
nuclear export
To test if ratjadone A specifically blocks the Rev-dependent
HIV mRNA nuclear export, TZM-bl cells transfected
with plasmids pCMVGagPol-RRE (Rev-dependent nuclear
export), pCMVGagPol-CTE (Rev-independent nuclear
export) and pCMVRev were incubated with RaTA or
LMB (as a control) and assayed for p24 expression by
immunofluorescence (Figure 5). As expected, cells trans-
fected with pCMVGagPol-RRE alone did not show p24
signals (Figure 5A-C). Levels of p24 from mock-treated
cells co-transfected with pCMVGagPol-RRE and pCMVRev
plasmids (Figure 5D) were set to 100% and relative in-
hibitory values were calculated (Figure 5J). RRE-Rev
Figure 5 Ratjadone A inhibits the Rev-dependent HIV-RNA nuclear export. TZM-bl cells were transfected with a GagPol-RRE plasmid
(A to C); co-transfected with GagPol-RRE and Rev expression plasmids (D to F) or with a GagPol-CTE expression plasmid (G to I). Cells were left
untreated or incubated with the indicated drugs at 2 nM (RaTA) and 4 nM (LMB) concentrations. 48 h after transfection cells were fixed and
stained for HIV-p24 protein (green signal) and DAPI (blue signal). Samples (A) to (C) serve as negative controls, and (D) as positive control. Arrows
in (H) indicate p24 positive cells. (J) The percentage of p24 positive cells for every sample is shown. Significant differences with p < 0.01 are
marked with asterisks. Error bars are standard error of the mean (SEM) of p24-positive cells counted in 10 microscopic fields.
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(Figure 5F) exhibited a significant decrease (to around 3%
and 20% of the untreated control, respectively) in p24 ex-
pression (p < 0.01 in both cases) (Figure 5J). The observed
lower levels of p24 expression by the pCMVGagPol-CTE
plasmid (around 30-40% of the control; Figure 5J) have
been noted in previous studies [32]. Despite this, p24-
positive cells were visible with or without drug addition
(Figure 5G-I). These results show that RaTA inhibition isspecific for the Rev-mediated HIV mRNA nuclear export
pathway.
Ratjadone A interacts with CRM1 but not with Rev
In order to investigate binding of RaTA to CRM1 and/or
Rev, we performed a drug affinity responsive target stabil-
ity (DARTS) assay. DARTS is based on the principle
that a protein is in a dynamic equilibrium with alternative
conformations. Ligand binding, mediated by hydrophobic,
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favors a specific conformation so that upon saturation
with a specific ligand, the equilibrium shifts towards the
ligand bound conformation. This leads to a thermodynam-
ically more stable state in which resistance to protease
degradation is markedly increased [33,34]. To test this in
the context of CRM1-Rev interaction, lysates from Rev-
transfected 293 T cells or HIV-infected MT-2 cells were
incubated with RaTA, LMB (positive control) or DMSO
(vehicle control). Samples were digested with a cocktail of
proteases and subjected to Western Blotting using specific
anti-CRM1 and anti-Rev antibodies. The Western Blot
bands of the target protein incubated with the drug should
be more intense than those of the target protein incubated
with DMSO as control. As shown in Figure 6, both RaTA
and LMB exert a clear protection band of around 110 kDa
that corresponds to CRM1 (Figure 6, lanes 3 and 4). The
relative protection of CRM1 exerted by the drugs was
more than 2-fold higher compared to the DMSO control
(Figure 6, lane 2). However, there was no significant pro-
tection of Rev (around 19 kDa) by the test compounds.
Rev appears as 2 close distinct bands in the positive con-
trol (Figure 6, lane 1). This 1-2 kDa shift could be due to
the partial phosphorylation of Rev as described before
[35-37]. No differences were observed when comparing
RaTA- or LMB-treated samples with the untreated control
(Figure 6, lane 2, 3 and 4 of Rev). At the pronase to pro-
tein ratio used in our assay (1:1000), tubulin is notFigure 6 Ratjadone A protects CRM1 from proteolysis. Lysates
from Rev-transfected 293 T cells were mock-treated with DMSO or
incubated with 200 nM ratjadone A or leptomycin B and digested
with Pronase. Samples were loaded on a SDS-PAGE gel and developed
by Western Blot (see Materials and methods). Lane 1: undigested
DMSO control; Lane 2: digested DMSO control; Lane 3: digested
sample incubated with RaTA; Lane 4: digested sample incubated
with LMB. Percentages of protection relative to undigested controls
are shown below the protein bands. Both RaTA and LMB protect
CRM1 (upper row) but not Rev (middle row) from degradation.
Tubulin was used as a loading control (lower row). The drug solvent
concentration (0.1% DMSO) in every sample was constant. Abbreviations:
RAT = Ratjadone A; LMB = Leptomycin B; DMSO= dimethyl sulfoxide;
n.a. = not applicable.significantly degraded. Therefore, it can be used as loading
control [33]. Similar results were obtained using lysates of
HIV-infected MT-2 cells (data not shown). These observa-
tions indicate that both RaTA and LMB exert their anti-
HIV activity by binding to CRM1 but not to Rev.
Discussion
The Rev-mediated HIV nuclear export step is an attractive
target for the development of new antivirals. Besides its
regulatory function, Rev has been associated with patho-
genesis as Rev-independent SIV clones seem to be attenu-
ated in monkeys [38]. Some argue that even a partial
blockade of Rev may contribute to virus control in vivo
[8]. So far, compounds directly acting on Rev-RRE have
low rates of viral inhibition [12,39] and are likely to gener-
ate drug-resistance mutants [40,41]. In a recent study, Naji
et al. found a strikingly high amount of cellular proteins
interacting with Rev that could also be explored as targets
for putative new anti-retroviral strategies [42]. The target-
ing of host-factors is an appealing alternative to conven-
tional antiviral drugs [43-49]. Compounds blocking viral
replication by acting on cellular components might reduce
the likelihood of resistance development and, if promis-
cuously used by several viruses, may even exert broad-
spectrum antiviral properties.
HIV uses the CRM1-mediated pathway for export of
RRE-containing viral mRNAs and the viral genomic RNA
out of the nucleus [2]. Remarkably, the CRM1-dependent
nuclear export pathway is shared by HIV and HTLV
[9,50-52], and it has been suggested to be preferentially
used by other clinically relevant viruses such as Dengue
Virus [53] and Hepatitis C virus [54]. Although these in-
teresting findings mark CRM1 as a putative good target
for broad-spectrum antivirals, the associated toxic effects
of CRM1 inhibitors have discouraged their further re-
search. The myxobacterial polyketide ratjadone A blocks
the CRM1-mediated nuclear export of mRNAs with a
similar mode of action as the related inhibitor leptomycin
B [26,27,55]. Although the basis of the CRM1-inhibition
by ratjadones is known, their effectiveness against HIV in-
fection was not previously defined. Here we show that rat-
jadone A inhibits HIV at the nanomolar range with a
higher intrinsic potency than leptomycin B. Ratjadone A
blocks the CRM1/Rev-mediated mRNA nuclear export by
binding to CRM1 but not to Rev. These results suggest
that treatment with ratjadones might not induce resistance
development, although further studies are needed to cor-
roborate this hypothesis.
Recently, it has been shown that sensitizing cells by
blocking CRM1 with low concentrations of ratjadone
improves the response to topoisomerase II treatment in
multiple myeloma cancer cells [56], and that related
CRM1 inhibitors are effective in T-cell leukaemic in vivo
models [57]. Likewise, CRM1 inhibitors may be tested as
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viral diseases. For this, the study of ratjadone derivatives
that exhibit diverse efficacies of blocking CRM1 [27] could
be an interesting direction to follow.
Conclusions
The myxobacterial metabolite ratjadone A is an efficient
HIV inhibitor by blocking the nuclear export protein
CRM1. Due to its mode of CRM1 inhibition and the low
selectivity index, the potential use of ratjadone A as a
mono-therapeutic antiviral is very limited. However, since
host-acting drugs are unlikely to generate resistance, fur-
ther studies including derivatives of ratjadones in combin-
ation with ART might help devise alternative antiretroviral
therapies in the future.
Materials and methods
Cell culture
293 T cells (ATCC, CRL-11268) were maintained at 37°C
and 5% CO2 in Dulbecco’s modified Eagle’s medium
(DMEM) (Gibco, Paisley, UK) supplemented with 10%
heat-inactivated fetal calf serum (FCS) and 1% penicillin-
streptomycin. TZM-bl cells (NIH AIDS Research and
Reference Reagent Program, catalogue number: 8129)
were maintained with DMEM supplemented with 10%
heat-inactivated FCS, HEPES 25 mM and 0.5% Gentamy-
cin. MT-2 (NIH AIDS Research and Reference Reagent
Program, catalogue number: 237) and PM1 cells (NIH
AIDS Research and Reference Reagent Program, catalogue
number: 3038) were maintained with RPMI medium
supplemented with 10% heat-inactivated FCS and 1% of
penicillin-streptomycin.
Plasmids
Plasmids pCMVGagPol-RRE, pCMVGagPol-CTE (a kind
gift from Kuan-Teh Jeang, NIAID, NIH, USA [58]) and
pCMV-Rev were used. Plasmid pCMVGalPol-RRE contains
the HIV-GagPol region and the Rev-responsive element
(RRE), pCMVGagPol-CTE contains the HIV-GagPol RNA
region and the Constitutive Transport Element (CTE) from
the Mason-Pfizer Monkey Virus (MPMV), and pCMV-
Rev expresses the HIV-Rev protein. Transfections in HEK
293 T and TZM-bl cells were performed with Lipofecta-
mine 2000 (Invitrogen, Paisley, UK) according to the man-
ufacturer’s manual. A pSV2-gpt expression plasmid was
used as negative control.
Drugs
Ratjadone A is from the collection of myxobacterial sec-
ondary metabolites of the Helmholtz Centre for Infection
Research, Braunschweig, Germany. Leptomycin B was
purchased from Sigma, St. Louis, USA. The entry inhibitor
Enfuvirtide (Fuzeon, Roche, Basel Switzerland) was usedas a positive control for the time-of-drug addition experi-
ments (TOA).
Virus stocks
HIV-1LAI isolate was obtained from the Centre for AIDS
Reagents, NIBSC (UK). Virus was propagated in PM1
cells, titrated and stored at -80°C. Infections were per-
formed in triplicate at a multiplicity of infection (MOI)
of 0.5. Infected TZM-bl cells were used to obtain EC50
and CC50 values and for TOA (see below) experiments.
MT-2 cells were infected for immunostaining and DARTS
assay (Section 2.8).
Dose-response assays
TZM-bl cells were plated (104 cells/well) in Nunc®
MicroWell 96 well optical bottom plates (Sigma) and in-
cubated for 1 h with increasing concentrations of test
compounds in 10-fold dilutions or with the correspond-
ing vehicle (DMSO or MeOH) as negative control in
triplicates. After drug incubation, cells were infected with
HIVLAI at MOI = 0.5. 48 h after infection luciferase ac-
tivity was measured using Britelite Plus™ (PerkinElmer,
Waltham, USA). In parallel, cell viability of TZM-bl cells
was determined with an ATP quantification method
using the commercial kit CellTiter-Glo® Luminescent
Cell Viability Assay (Promega, Madison, USA). ATP is a
marker of the presence of metabolically active cells [59].
Therefore, the ATP levels relative to the untreated con-
trol are a measure of drug-induced cytotoxicity. Mean
luciferase values were normalized to untreated controls
and Effective Concentration 50 (EC50) and Cytotoxic
Concentration 50 (CC50) were calculated in GraphPad
Prism (GraphPad Software, San Diego, CA, USA) by
analyzing the logdose vs. normalized response. The Select-
ivity Index (SI) refers to the antiviral potency of a drug
and is calculated as the ratio of CC50 to EC50 [60,61].
For western blotting, proteins of cell lysates were sepa-
rated on a SDS-PAGE and transferred to nitrocellulose
membranes (Whatman, Dassel, Germany). Western Blots
were developed with anti-HIV-1 p24 (NIBSC, UK) and
anti-mouse IgG-Horseradish peroxidase (GE Healthcare,
Bio-Sciences, Little Chalfont, UK) as primary and second-
ary antibodies, respectively. Bands were detected using
SuperSignal® West Femto Maximum Sensitivity Substrate
(Thermo scientific, Waltham, USA) and visualized with a
LumiImager (LAS-1000). Protein bands were quantified
by densitometric scanning using Image Gauge software
(Fuji Photo Film Co, Ltd, Tokyo, Japan).
Immunofluorescence
TZM-bl cells were plated on poly-L-lysine-coated mi-
croscopy glasses (Thermoscientific) and transfected with
plasmids pCMVRev, pCMVGagPol-RRE or pCMVGagPol-
CTE. 48 h after transfection, glasses were fixed in PBS
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(20 minutes in 0.2% Triton X-100; Sigma) and blocking
(30 minutes with FCS 10%), samples were stained for 1 h
with anti-HIV p24 antibody provided by the Centre for
AIDS Reagents, NIBSC (UK), and a secondary anti-mouse
IgG antibody labelled with Alexa Fluor 647 (Invitrogen)
for 45 minutes in the dark, followed by a 15 minutes nu-
clear staining with DAPI. Glasses were placed in micros-
copy slides with Mowiol (Sigma) and examined with the
Leica TCS SP2 confocal microscope at 40× magnification
(to count cells) and Leica TCS SP5 at 63× (to take pic-
tures). MT-2 cells were infected and stained following the
same protocol.
Time of drug addition experiment (TOA)
The TOA protocol was performed as described [30,31].
Briefly, TZM-bl cells (106 cells) were synchronously in-
fected with HIVLAI virus at a MOI of 0.5 by spinoculation
at 4°C for 90 minutes at 300 g [62]. After three washing
steps with cold PBS to remove unattached virus, cells were
plated into a 96-well optical plate and the infection
was synchronized through adding culture medium at
37°C, defining time 0 h of the experiment. Then 10 nM
of ratjadone A was added at the indicated time points
post-infection. 1 μM of T20 was added as a control.
Luciferase activity was measured with Britelite Plus™
(PerkinElmer) 72 h after infection.
Drug affinity responsive target stability (DARTS) assay
The DARTS assay was developed by Lomenick et al.
[33] and is based on the property of small molecules to
protect their targets from protease degradation. Briefly,
Rev-transfected 293 T cells and HIV-infected MT-2 cells
were lysed with M-Per lysis buffer (Thermoscientific)
containing a mixture of protease inhibitors to avoid en-
dogenous protein degradation. Lysates were incubated at
room temperature for 1 h either with RaTA, LMB or left
untreated, and digested with Pronase (Roche) at a prote-
ase to protein ratio of 1:1000 for 30 minutes. Digestion
was stopped by addition of SDS-PAGE loading buffer
(with SDS and mercaptoethanol) and heating for 5 mi-
nutes at 95°C [33]. Samples were run on a SDS-PAGE
electrophoresis gel and were transferred to nitrocellulose
membranes (Whatman, Dassel, Germany). Western Blots
were developed with anti-CRM1 (Abcam, Cambridge,
UK) and anti-α-tubulin (SIGMA) as primary antibodies.
Anti-rabbit or anti-mouse fluorescent-labelled anti-
bodies (LI-COR, Lincoln, USA) were used as secondary
antibodies. Membranes were visualized with a scanner
Odyssey®CLx and analyzed by densitometric scanning of
the bands with the Odyssey software V3.0 (LI-COR).
Rev bands were stained with anti-Rev (NIBSC, UK) and
anti-mouse IgG-Horseradish peroxidase (GE Healthcare,
Bio-Sciences, Little Chalfont, UK) as primary and secondaryantibody, respectively. Bands were detected using Super-
Signal® West Femto Maximum Sensitivity Substrate
(Thermo scientific, Waltham, USA) and visualized as
described above.
Abbreviation
CRM1: Chromosome Region Maintenance 1.
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